Theravance Biopharma, Inc. (TBPH)
17.01
0.00 (0.00%)
USD |
NASDAQ |
Aug 24, 16:00
17.00
-0.01
(-0.06%)
After-Hours: 20:00
Theravance Biopharma Gross Profit Margin (Quarterly) : 93.04% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 93.04% |
| March 31, 2026 | 91.88% |
| December 31, 2025 | 96.72% |
| September 30, 2025 | 92.96% |
| June 30, 2025 | 94.85% |
| March 31, 2025 | 91.04% |
| December 31, 2024 | 92.72% |
| September 30, 2024 | 90.76% |
| June 30, 2024 | 89.07% |
| March 31, 2024 | 89.43% |
| December 31, 2023 | 90.21% |
| September 30, 2023 | 91.47% |
| June 30, 2023 | 90.27% |
| March 31, 2023 | 84.10% |
| December 31, 2022 | 91.48% |
| September 30, 2022 | 86.95% |
| June 30, 2022 | 82.43% |
| March 31, 2022 | 89.99% |
| December 31, 2021 | 93.12% |
| September 30, 2021 | 80.06% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| Date | Value |
|---|---|
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 56.88% |
| December 31, 2018 | 90.53% |
| September 30, 2018 | 89.69% |
| June 30, 2018 | |
| March 31, 2018 | 84.66% |
| December 31, 2017 | 30.99% |
| September 30, 2017 | 76.96% |
| June 30, 2017 | 61.13% |
| March 31, 2017 | 64.16% |
| December 31, 2016 | 69.54% |
| September 30, 2016 | 94.11% |
| June 30, 2016 | 88.34% |
| March 31, 2016 | 95.77% |
| December 31, 2015 | 17.80% |
| September 30, 2015 | 91.20% |
| June 30, 2015 | 88.75% |
| March 31, 2015 | 96.75% |
| December 31, 2014 | -124.8% |
| September 30, 2014 | 77.21% |
| June 30, 2014 | 67.55% |
| March 31, 2014 | 2.65% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Zymeworks, Inc. | 57.43% |
| Viatris, Inc. | 41.92% |
| Ocular Therapeutix, Inc. | 85.08% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 20.16% |
| Return on Assets | 11.86% |
| Return on Invested Capital | 16.35% |
| Profit Margin (Quarterly) | -28.45% |
| Operating Margin (Quarterly) | -2.91% |
| Return on Net Operating Assets | 83.44% |